Mostrar el registro sencillo del ítem
dc.contributor.author | Jimenez-Sousa, Maria Angeles | |
dc.contributor.author | Gómez-Moreno, Ana Zaida | |
dc.contributor.author | Pineda-Tenor, Daniel | |
dc.contributor.author | Sánchez-Ruano, Juan José | |
dc.contributor.author | Artaza-Varasa, Tomas | |
dc.contributor.author | Martin-Vicente, Maria | |
dc.contributor.author | Fernandez-Rodriguez, Amanda | |
dc.contributor.author | Martinez, Isidoro | |
dc.contributor.author | Resino, Salvador | |
dc.date.accessioned | 2020-02-10T12:03:27Z | |
dc.date.available | 2020-02-10T12:03:27Z | |
dc.date.issued | 2019 | |
dc.identifier.citation | Biomolecules. 2019 Apr 9;9(4). pii: E143. | es_ES |
dc.identifier.issn | 2218-273X | es_ES |
dc.identifier.uri | http://hdl.handle.net/20.500.12105/9070 | |
dc.description.abstract | The Duffy antigen receptor for chemokines (DARC) rs12075 polymorphism regulates leukocyte trafficking and proinflammatory chemokine homeostasis. Hepatitis C virus (HCV)-mediated liver fibrosis is associated with an uncontrolled inflammatory response. In this study, we evaluate the association between the DARC rs12075 polymorphism and liver stiffness progression in HCV-infected patients. We carried out a retrospective cohort study (repeated measures design) in 208 noncirrhotic patients with chronic hepatitis C (CHC) who had at least two liver stiffness measurements (LSM) with a separation of at least 12 months. We used generalized linear models to analyze the association between DARC rs12075 polymorphism and outcome variables. During a follow-up of 46.6 months, the percentage of patients with stages of fibrosis F0/F1 decreased (p < 0.001), while LSM values and the percentage of patients with cirrhosis increased (p < 0.001). This pattern of changes was maintained in each of the groups of patients analyzed according to their rs12075 genotypes (AA or AG/GG). However, the variations in liver stiffness characteristics were lower in patients with the rs12075 AG/GG genotype (AG/GG versus AA). Thereby, in the adjusted analysis, patients with the rs12075 AG/GG genotype had a lower risk of an increased value of LSM2/LSM1 arithmetic mean ratio (AMR = 0.83; p = 0.001) and of an increase in LSM ≥ 5 kPa (odds ratio (OR) = 0.28; p = 0.009). Besides, patients with rs12075 AG/GG had a lower risk of cirrhosis progression (OR = 0.24; p = 0.009). No significant associations were found for an increase in LSM ≥ 10 kPa. We found an association between the DARC rs12075 single nucleotide polymorphism (SNP) and CHC progression. Specifically, patients with the DARC rs12075 AG/GG genotype had a lower risk of liver fibrosis progression and development of cirrhosis. | es_ES |
dc.description.sponsorship | This work has been supported by a grant given by the Instituto de Salud Carlos III (ISCIII) (grant number PI17CIII/00003). The study was approved by the Research Ethic Committee of the Instituto de Salud Carlos III and was conducted in accordance with the Declaration of Helsinki. All patients gave their written informed consent. | es_ES |
dc.language.iso | eng | es_ES |
dc.publisher | Multidisciplinary Digital Publishing Institute (MDPI) | es_ES |
dc.type.hasVersion | VoR | es_ES |
dc.rights.uri | http://creativecommons.org/licenses/by/4.0/ | * |
dc.subject | DARC | es_ES |
dc.subject | Chronic hepatitis C | es_ES |
dc.subject | Cirrhosis | es_ES |
dc.subject | Hepatic fibrosis | es_ES |
dc.subject | Liver stiffness | es_ES |
dc.subject | Single nucleotide polymorphisms | es_ES |
dc.subject.mesh | Adult | es_ES |
dc.subject.mesh | Duffy Blood-Group System | es_ES |
dc.subject.mesh | Female | es_ES |
dc.subject.mesh | Hepatitis C, Chronic | es_ES |
dc.subject.mesh | Humans | es_ES |
dc.subject.mesh | Liver | es_ES |
dc.subject.mesh | Liver Cirrhosis | es_ES |
dc.subject.mesh | Male | es_ES |
dc.subject.mesh | Middle Aged | es_ES |
dc.subject.mesh | Receptors, Cell Surface | es_ES |
dc.subject.mesh | Polymorphism, Single Nucleotide | es_ES |
dc.title | Impact of DARC rs12075 Variants on Liver Fibrosis Progression in Patients with Chronic Hepatitis C: A Retrospective Study | es_ES |
dc.type | journal article | es_ES |
dc.rights.license | Atribución 4.0 Internacional | * |
dc.identifier.pubmedID | 30970632 | es_ES |
dc.format.volume | 9 | es_ES |
dc.format.number | 4 | es_ES |
dc.format.page | 143 | es_ES |
dc.identifier.doi | 10.3390/biom9040143 | es_ES |
dc.contributor.funder | Instituto de Salud Carlos III | |
dc.description.peerreviewed | Sí | es_ES |
dc.identifier.e-issn | 2218-273X | es_ES |
dc.relation.publisherversion | https://doi.org/10.3390/biom9040143 | es_ES |
dc.identifier.journal | Biomolecules | es_ES |
dc.repisalud.centro | ISCIII::Centro Nacional de Microbiología | es_ES |
dc.repisalud.institucion | ISCIII | es_ES |
dc.relation.projectID | info:eu-repo/grantAgreement/ES/PI17CIII/00003 | es_ES |
dc.rights.accessRights | open access | es_ES |